Latest Safety News

St Barbara Limited has closed a A$389 million investment deal with Lingbao Gold Group, greenlighting a US$333 million expansion of the New Simberi Gold Project and securing key environmental approvals for its Nova Scotia operations.

Grange Resources delivered a steady first quarter in 2026 with solid production at Savage River, no lost time injuries for nearly three years, and progressing financing for its North Pit Underground project.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Centaurus Metals has secured a binding offtake deal with Glencore and attracted up to US$320 million in financing offers for its Jaguar Nickel Project, while advancing exploration and pilot testing at its Brazilian copper-gold and iron ore assets.

Beach Energy’s Q3 FY26 output rose 7% quarter-on-quarter, led by a 174% surge in Perth Basin production following Waitsia Gas Plant compressor commissioning. The company also secured new Queensland acreage and greenlit the Moomba Central Optimisation project, though weather disruptions trimmed Cooper Basin output and prompted a production guidance cut.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Central Petroleum lifted March quarter sales revenue to $11.3 million, driven by higher gas volumes and prices, while securing a significant multi-year gas supply deal with the Northern Territory Government that supports a 40% production capacity increase at Palm Valley.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.